---
title: "Pharming Group N.V. (PHAR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PHAR.US.md"
symbol: "PHAR.US"
name: "Pharming Group N.V."
industry: "Biotechnology"
datetime: "2026-05-21T12:20:39.801Z"
locales:
  - [en](https://longbridge.com/en/quote/PHAR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHAR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHAR.US.md)
---

# Pharming Group N.V. (PHAR.US)

## Company Overview

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.pharming.com](https://www.pharming.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: B (0.30)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 36 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.21% |  |
| Net Profit YoY | 187.56% |  |
| P/B Ratio | 3.38 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 908946710.10 |  |
| Revenue | 369487000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.12% | C |
| Profit Margin | 3.34% | C |
| Gross Margin | 90.83% | A |
| Revenue YoY | 15.21% | B |
| Net Profit YoY | 187.56% | A |
| Total Assets YoY | 21.38% | A |
| Net Assets YoY | 24.93% | A |
| Cash Flow Margin | 456.65% | A |
| OCF YoY | 15.21% | B |
| Turnover | 0.83 | B |
| Gearing Ratio | 45.04% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Pharming Group N.V.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.21%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "187.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.38",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "908946710.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "369487000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.12%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "3.34%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "90.83%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "15.21%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "187.56%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.38%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "24.93%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "456.65%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "15.21%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.83",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "45.04%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 73.56 | 55/385 | 3147.73 | 2909.19 | 405.15 |
| PB | 3.38 | 265/385 | 4.37 | 4.11 | 3.46 |
| PS (TTM) | 2.46 | 56/385 | 3.19 | 2.95 | 2.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.87 |
| Highest Target | 41.00 |
| Lowest Target | 23.40 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PHAR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PHAR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PHAR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PHAR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**